concept

CRISPR

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CRISPR: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

15Connections

11Hypotheses

4Analyses

7Outgoing

8Incoming

4Experiments

4Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	CRISPR
Key Genes/Proteins	Cell-type-specific essential genes, Disease-causing mutations with integrated reporters, NURR1, PITX3, neuronal identity transcription factors, PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes
Related Diseases	Amyotrophic Lateral Sclerosis
Linked Hypotheses	12 hypotheses

Wiki Pages (13)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    CRISPR[CRISPR]
    CRISPR -->|targets| Central_Nervous_System[Central Nervous System]
    CRISPR -->|mediates| Epigenetic_Modifications[Epigenetic Modifications]
    CRISPR -->|targets| APOE[APOE]
    CRISPR -->|promotes| Metabolic_Reprogramming[Metabolic Reprogramming]
    CRISPR -->|edits| Mitochondrial_Genome[Mitochondrial Genome]
    CRISPR -->|targets| Adult_Neurons[Adult Neurons]
    CRISPR -->|activates| Misfolded_Protein_Aggregates[Misfolded Protein Aggregates]
    CRISPR -->|inhibits| MSH3[MSH3]
    CRISPR -->|inhibits| PMS1[PMS1]
    CRISPR -->|treats| Amyotrophic_Lateral_Sclerosis[Amyotrophic Lateral Sclerosis]
    SDA_2026_04_02_gap_crispr_neur[SDA-2026-04-02-gap-crispr-neurodegeneration-20260402] -->|investigates| CRISPR
    Viral_Vector[Viral Vector] -->|mediates| CRISPR
    exosome[exosome] -->|interacts| CRISPR
    blood_brain_barrier[blood brain barrier] -->|inhibits| CRISPR
    Cell_type_specific_essential_g[Cell-type-specific essential genes] -->|co_associated_with| CRISPR
    PGC1A__SIRT1__FOXO3__mitochond[PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes] -->|co_associated_with| CRISPR
    NURR1__PITX3__neuronal_identit[NURR1, PITX3, neuronal identity transcription factors] -->|co_associated_with| CRISPR
    Disease_causing_mutations_with[Disease-causing mutations with integrated reporters] -->|co_associated_with| CRISPR

Outgoing (7)

Target	Relation	Type	Str
Central Nervous System	targets	brain_region	0.95
Epigenetic Modifications	mediates	process	0.95
APOE	targets	gene	0.90
Metabolic Reprogramming	promotes	process	0.90
Adult Neurons	targets	cell_type	0.85
Amyotrophic Lateral Sclerosis	treats	disease	0.70
Alzheimer's Disease	treats	disease	0.70

Incoming (8)

Source	Relation	Type	Str
SDA-2026-04-02-gap-crispr-neurodegeneration-20260402	investigates	analysis	0.95
Viral Vector	mediates	compound	0.85
exosome	interacts_with	compound	0.85
blood brain barrier	inhibits	brain_region	0.80
Cell-type-specific essential genes	co_associated_with	gene	0.30
PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes	co_associated_with	gene	0.30
NURR1, PITX3, neuronal identity transcription factors	co_associated_with	gene	0.30
Disease-causing mutations with integrated reporters	co_associated_with	gene	0.30

Targeting Hypotheses (11)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Context-Dependent CRISPR Activation in Specific Neuronal Sub	0.682	neurodegeneration	CRISPR-based therapeutic approaches for
Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mi	0.681	neurodegeneration	CRISPR-based therapeutic approaches for
CRISPR-Mediated Mitochondrial Genome Editing for Complex I D	0.681	neurodegeneration	CRISPR-based therapeutic approaches for
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo	0.638	neurodegeneration	CRISPR-based therapeutic approaches for
Programmable Neuronal Circuit Repair via Epigenetic CRISPR	0.630	neurodegeneration	CRISPR-based therapeutic approaches for

Multi-Modal CRISPR Platform for Simultaneous Editing and Mon	0.629	neurodegeneration	CRISPR-based therapeutic approaches for
Cholesterol-CRISPR Convergence Therapy for Neurodegeneration	0.622	neurodegeneration	CRISPR-based therapeutic approaches for
Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Tar	0.613	neurodegeneration	CRISPR-based therapeutic approaches for
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Ci	0.599	neurodegeneration	CRISPR-based therapeutic approaches for
Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromat	0.544	neurodegeneration	CRISPR-based therapeutic approaches for
Conditional CRISPR Kill Switches for Aberrant Protein Cleara	0.496	neurodegeneration	CRISPR-based therapeutic approaches for

Mentioning Analyses (4)

Scientific analyses that reference this entity

What molecular mechanisms explain how KCNJ2 inhibition mitigates TBI-induced neu

neurodegeneration | 2026-04-13 | 0 hypotheses

How can CRISPR systems achieve persistent therapeutic effects while avoiding chr

gene therapy | 2026-04-11 | 0 hypotheses

CRISPR-based therapeutic approaches for neurodegenerative diseases

neurodegeneration | 2026-04-03 | 14 hypotheses Top: 0.803

CRISPR-based therapeutic approaches for neurodegenerative diseases

neurodegeneration | 2026-04-02 | 0 hypotheses

Experiments (4)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Acteoside treatment in LPS-induced SALI mouse model	validation	sepsis-associated acute lung i	0.900	0.00	LPS-induced SALI mouse model	proposed	N/A
Nrf2 inhibitor ML385 mechanism validation experiment	exploratory	sepsis-associated acute lung i	0.850	0.00	RAW264.7 cells and/or mouse mo	proposed	N/A
Acteoside effects on RAW264.7 macrophage cells	exploratory	sepsis-associated acute lung i	0.850	0.00	RAW264.7 cells	proposed	N/A
CRISPR Gene Correction Approaches for CBS/PSP	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$6,550,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Autophagy and ALS: mechanistic insights and therapeutic implications. [PMID:34057020]	Chua JP, De Calbiac H, Kabashi E, Barmad	Autophagy	2022	2
Exploring Parkinson's through the Lens of Genomics and Bioinformatics. [PMID:39929729]	Menon V	Cold Spring Harb Perspect Med	2026	0
Mismatch repair MLH complexes make distinct contributions to post-replicative mi [PMID:41648604]	Casazza KM, Williams GM, Johengen L, Kel	bioRxiv	2026	0
A Simple Method for RNA-Seq of Manually Isolated Chromatophores in Oryzias Fishe [PMID:41805030]	Goda M, Miyagi A, Sugiwaka K, Watanabe M	Dev Growth Differ	2026	0
Genome editing in Parkinson's disease: Unlocking therapeutic avenues through CRI [PMID:41905621]	["Singh R", "Maity P", "Jaiswal C"]	Neurochemistry international	2026	0
Targeting Non-coding RNAs in Neurodegeneration: Advances in Therapeutic RNA Moda [PMID:41588889]	["Thakur A", "Chowdhury K", "Kumar A", "	Current Alzheimer research	2026	0
Cell-type resolved protein atlas of brain lysosomes identifies SLC45A1-associate [PMID:41576950]	["Ghoochani A", "Heiby J", "Rawat E", "M	Cell	2026	0
Decoding Alzheimer's genetic risk through intercellular communication in the hum [PMID:41707523]	Lish AM, Young-Pearse TL	Current opinion in neurobiolog	2026	0
Neuromodulatory role and therapeutic potential of N 6 -methyladenosine RNA methy [PMID:40618260]	Zhang J, Ma W, Liu R, Li X, Yuan Z, Chen	Neural regeneration research	2026	0
Hereditary Polyneuropathies in the Era of Precision Medicine: Genetic Complexity [PMID:41595476]	["Chrysostomaki M", "Chatzi D", "Kyriako	Genes	2026	0
Neuroinflammation, Autophagy, and Neurodegeneration: Mechanisms and Therapeutic [PMID:41918200]	["Khanal P", "Balmik A"]	CNS & neurological disorders d	2026	0
Single-Cell Atlas of Transcription and Chromatin States Reveals Regulatory Progr [PMID:41676679]	Xie Y, Chang L, Zhong G, Rink JA, Báez-B	bioRxiv : the preprint server	2026	0
Targeting a Shared Mitophagy Regulator: The SIRT1-FOXO3-DEPP1 Axis Underpins the [PMID:41743852]	Zhang Y, Guo X, Wang Q, Xiao L, Liu Q, G	Research (Washington, D.C.)	2026	0
Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disea [PMID:39824182]	["Handsaker R", "Kashin S", "Reed N", "T	Cell	2025	0
Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through ta [PMID:39700958]	["Abdelaziz A", "Rasheed N", "Zaki H", "	International immunopharmacolo	2025	0
Metabolic rewiring prevents neurodegeneration caused by chronic mitochondrial dy [PMID:41151583]	Richhariya S, Shin D, Schlichting M, Ros	Current biology : CB	2025	0
CRISPR-Cas technologies in neurodegenerative disorders: mechanistic insights, th [PMID:41674784]	["Yashooa R", "Nabi A", "Smail S", "Azee	Frontiers in neurology	2025	0
HMGCR genetic variability in Parkinson's disease in a Spanish cohort: associatio [PMID:41037108]	Díaz-Belloso R, Martín-Bornez M, Macías-	Journal of neurology	2025	0
Nurr1 modulators - a patent review (2019-present). [PMID:40481732]	["Egner M", "Merk D"]	Expert opinion on therapeutic	2025	0
VDAC2 loss elicits tumour destruction and inflammation for cancer therapy. [PMID:40108474]	Yuan S, Sun R, Shi H, Chapman NM, Hu H,	Nature	2025	0

Debates (4)

Multi-agent debates referencing this entity

The debate highlighted that long-term CRISPR expression triggers immune response

closed · Rounds: 4 · Score: 0.50 · 2026-04-18

The study identifies KCNJ2 as a therapeutic target through CRISPR screening but

closed · Rounds: 4 · Score: 0.71 · 2026-04-16

Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for

closed · Rounds: 4 · Score: 0.95 · 2026-04-03

Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for

closed · Rounds: 4 · Score: 0.90 · 2026-04-02

Related Research

Hypotheses and analyses mentioning CRISPR in their description or question text

Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring

Score: 0.629 · neurodegeneration · 2026-04-02

## Mechanistic Overview Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring starts from the claim that m

Cholesterol-CRISPR Convergence Therapy for Neurodegeneration

Score: 0.622 · neurodegeneration · 2026-04-02

## Mechanistic Overview Cholesterol-CRISPR Convergence Therapy for Neurodegeneration starts from the claim that modulati

Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting

Score: 0.613 · neurodegeneration · 2026-04-02

## Mechanistic Overview Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting starts from the claim that mo

Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits

Score: 0.599 · neurodegeneration · 2026-04-02

## Mechanistic Overview Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits starts from the claim that mo

Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromatin Remodeling

Score: 0.544 · neurodegeneration · 2026-04-04

## Mechanistic Overview Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromatin Remodeling starts from the claim

Conditional CRISPR Kill Switches for Aberrant Protein Clearance

Score: 0.496 · neurodegeneration · 2026-04-04

## Mechanistic Overview Conditional CRISPR Kill Switches for Aberrant Protein Clearance starts from the claim that modul

CRISPR

Understanding Entity Pages

Wiki Pages (13)

CRISPR Gene Editing in Neurodegeneration

CRISPR Gene Editing for Parkinson's Disease

Section 107: CRISPR-Based Therapies in CBS/PSP

CRISPRi Epigenetic Silencing of SNCA for Parkinson's Disease

CRISPR Gene Editing for Neurodegeneration

Section 241: Advanced Gene Therapy and CRISPR Approaches in CBS/PSP

CRISPR and Genome Editing Brain Delivery

Epigenetic Editing and CRISPR Approaches in CBS/PSP

CRISPR Gene Editing for Neurodegenerative Diseases

CRISPR-Cas9 Gene Editing for Neurodegenerative Diseases

CRISPR Gene Correction Approaches for CBS/PSP

CRISPR/Cas9 Gene Therapy for Neurodegeneration

CRISPR Therapeutics

Pathway Diagram

Outgoing (7)

Incoming (8)

Targeting Hypotheses (11)

Mentioning Analyses (4)

What molecular mechanisms explain how KCNJ2 inhibition mitigates TBI-induced neu

How can CRISPR systems achieve persistent therapeutic effects while avoiding chr

CRISPR-based therapeutic approaches for neurodegenerative diseases

CRISPR-based therapeutic approaches for neurodegenerative diseases

Experiments (4)

Related Papers (20)

Debates (4)

The debate highlighted that long-term CRISPR expression triggers immune response

The study identifies KCNJ2 as a therapeutic target through CRISPR screening but

Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for

Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for

Related Research

Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring

Cholesterol-CRISPR Convergence Therapy for Neurodegeneration

Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting

Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits

Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromatin Remodeling

Conditional CRISPR Kill Switches for Aberrant Protein Clearance